> Research Use Only: The compounds discussed in this article are intended for scientific research purposes only. They are not approved for human use, therapeutic applications, or self-administration. This content is provided for educational and informational purposes only and does not constitute medical advice.
# Epithalon (Epitalon) Research Profile 2026: Telomerase, Pineal Regulation, and the Evidence Landscape
Epithalon (also spelled Epitalon; chemical name AEDG for its amino acid sequence Ala-Glu-Asp-Gly) is a synthetic tetrapeptide developed from epithalamin, a pineal gland extract shown in Soviet-era research to extend lifespan and modulate circadian function in rodents. As the minimal active sequence of this extract, Epithalon has been extensively studied by Vladimir Khavinson and colleagues at the Saint Petersburg Institute of Bioregulation and Gerontology — a research program spanning more than two decades and producing one of the largest bodies of literature on any single research peptide.
Epithalon occupies a distinctive position in longevity research: it is one of the few peptide compounds with published data on telomerase activation in human cells in vitro, meaningful lifespan extension in multiple animal models, and a modest but real body of clinical data from the Khavinson group. At the same time, the evidence base has significant limitations — most human data comes from one research center, randomized controlled trials in humans are sparse, and replication by independent groups is limited. Researchers approaching Epithalon should engage with both the compelling mechanistic findings and this evidence qualification honestly.
---
Compound Overview
| Property | Details |
|---|---|
| Sequence | Ala-Glu-Asp-Gly (tetrapeptide, 4 amino acids) |
| Molecular weight | ~390 Da |
| Source origin | Derived from epithalamin (pineal gland extract) |
| CAS number | 307297-39-8 |
| Primary mechanisms studied | Telomerase (hTERT) activation, melatonin upregulation, antioxidant gene induction |
| Regulatory status | Research use only; no FDA approval for any indication |
| Principal investigator | Vladimir Khavinson, St. Petersburg Institute of Bioregulation |
---
Development History and the Khavinson Research Program
Epithalon emerged from a broader program of peptide bioregulator research initiated in the Soviet Union in the 1970s. Khavinson and colleagues at the USSR Military Medical Academy developed epithalamin — a crude polypeptide extract of bovine and ovine pineal glands — and demonstrated that it extended the lifespan of rodents and influenced neuroendocrine function, particularly melatonin synthesis and circadian rhythm regulation.
To identify the minimal active pharmacophore of epithalamin, Khavinson's group synthesized individual short peptide sequences and tested their biological activity. The tetrapeptide Ala-Glu-Asp-Gly (AEDG, branded as Epithalon) was identified as retaining the key biological activities of the parent extract in a defined, synthesizable form. This work was published across Russian-language literature through the 1990s and began appearing in indexed international journals in the early 2000s.
The Khavinson program has since produced over 40 publications on Epithalon across cell culture, rodent, primate, and limited human studies. This volume of data from a single research group — while impressive in scope — creates a replication limitation that independent researchers should note when evaluating the evidence.
---
Mechanism of Action
Telomerase Activation (hTERT Upregulation)
Epithalon's most widely cited mechanism is activation of telomerase via upregulation of human telomerase reverse transcriptase (hTERT) gene expression. Telomerase is the enzyme that maintains telomere length at chromosome ends; in most somatic cells it is epigenetically silenced after early development, and progressive telomere shortening with each cell division contributes to replicative senescence. Reactivating telomerase has been studied as a potential anti-aging strategy.
Khavinson et al. published cell culture studies demonstrating that Epithalon treatment increased hTERT mRNA expression and telomerase enzyme activity in human fetal fibroblasts, extending their Hayflick limit (maximum replicative divisions) in culture. The mechanism proposed is that the tetrapeptide acts as a short regulatory peptide (a "geroprotective peptide") that interacts with chromatin-associated proteins to modulate gene expression, potentially functioning as a histone-associated signal in the epigenetic regulation of aging-related genes.
While this mechanism is pharmacologically interesting, researchers should note that telomerase activation in somatic cells also increases cancer risk theoretically (telomerase reactivation is a hallmark of malignant cells). The Khavinson group's studies in rodents did not show increased tumor incidence, but this safety question remains important for any translational consideration.
Pineal and Melatonin Regulation
The pineal gland produces melatonin, the circadian master hormone that coordinates sleep-wake cycles and seasonal biology. Epithalon was found to restore age-related decline in melatonin production in aging rodents and primates. Anisimov et al. demonstrated that both epithalamin and Epithalon increased pineal activity and melatonin secretion in aged rats, and that this correlated with improvements in circadian rhythm parameters.
Melatonin has its own documented antioxidant and potentially geroprotective properties, so some of Epithalon's observed effects may be partially mediated through restored melatonin production rather than direct cellular action. This mechanistic ambiguity is another area where independent mechanistic dissection is needed.
Antioxidant and DNA Repair Induction
Multiple Khavinson group studies report that Epithalon treatment upregulates antioxidant enzyme expression (superoxide dismutase, catalase, glutathione peroxidase) and promotes DNA repair pathway activity in cell culture models. Reduced oxidative damage and enhanced DNA repair are mechanistically plausible contributions to a longevity or anti-aging profile, but these findings require independent replication.
---
Key Research Findings
Animal Lifespan Studies
The most compelling data supporting Epithalon's anti-aging potential comes from rodent lifespan studies. Anisimov et al. (2003) reported that Epithalon treatment increased mean lifespan by approximately 13% and maximum lifespan by 16% in mice relative to controls. Additional studies in fruit flies (Drosophila melanogaster) reported lifespan extension of up to 30% with Epithalon treatment (Khavinson et al., 2003;.
In SHR (spontaneously hypertensive) rats and in carcinogen-exposed rodent models, Epithalon and epithalamin treatment reduced tumor incidence and delayed tumor appearance compared to controls — a finding that appears to run counter to theoretical telomerase-related cancer risk concerns, though the rodent cancer models may not fully model human carcinogenesis.
Primate Research
Khavinson's group extended studies to rhesus monkeys, reporting improved melatonin secretion, restored reproductive hormone profiles, and reduced markers of oxidative stress in aged primates treated with Epithalon over multiple years. These findings in a non-human primate model closer to human physiology represent a significant step beyond rodent data, though the sample sizes were small.
Human Clinical Data
The most limited tier of evidence involves human studies. Khavinson et al. published data from older patients receiving pineal peptide preparations (including Epithalon) and reporting improvements in melatonin levels, circadian rhythm normalization, and markers of immune and neuroendocrine function. These studies were generally observational or had limited controls, precluding strong conclusions about efficacy. No large, independent, randomized controlled trials on Epithalon have been published to date.
---
Research Applications
Telomere Biology and Cellular Aging: Epithalon's documented hTERT upregulation makes it a research tool for studying the pharmacological control of telomerase in cell culture models. Researchers studying replicative senescence, the Hayflick limit, or telomere length dynamics may use Epithalon as a probe compound alongside established controls.
Pineal/Circadian Research: Epithalon's melatonin-restoring activity in aged animal models makes it relevant for researchers studying the circadian regulation of aging, age-related decline in pineal function, or melatonin's role in systemic aging biology.
Geroprotective Peptide Pharmacology: As part of the broader class of short bioregulatory peptides identified by Khavinson's group, Epithalon is studied alongside other tetrapeptides (Vilon, Thymalin) as a model for understanding how endogenous short peptides may regulate gene expression and cellular aging programs.
Oxidative Stress Models: Antioxidant enzyme upregulation data supports use of Epithalon in oxidative stress research designs, though mechanistic specificity relative to direct antioxidants needs experimental design attention.
---
Safety Profile and Limitations
Published Safety Data: In the rodent and primate studies cited by Khavinson's group, Epithalon did not produce overt toxicity, and as noted, did not increase tumor incidence — an important finding given theoretical telomerase concerns. However, the safety data in humans is extremely limited.
Evidence Tier Limitations: The most critical limitation of the Epithalon evidence base is the concentration of research within one group at one institution. Independent replication of the telomerase activation, lifespan extension, and clinical findings by researchers outside the Khavinson program is a pressing scientific need. Researchers should approach the published literature with appropriate skepticism about effect sizes until independent replication data exists.
Publication Bias Risk: The preponderance of positive findings from the Khavinson group, without counterbalancing null results from independent groups, raises standard concerns about publication bias in the available literature.
No Human RCT Data: There are no published large-scale, double-blind, randomized controlled trials of Epithalon in human participants with validated biomarker or clinical outcomes. This is the most significant gap between the animal and mechanistic data and translational conclusions.
---
Sourcing on Peptides.SO
Epithalon is listed by multiple research peptide suppliers on Peptides.SO. Our Epithalon comparison page aggregates verified supplier pricing and CoA data. The tetrapeptide's small size (~390 Da) requires verification of correct sequence and cyclization state. Researchers should confirm via mass spectrometry data that supplied material matches the Ala-Glu-Asp-Gly sequence. Given the small molecular weight, purity assessment by HPLC and identity confirmation by MS are the minimum quality standards for research-grade material.
---
References
1. Khavinson VK, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-592. PMID: 12937682
2. Anisimov VN, Arutjunyan AV, Khavinson VK. Effects of pineal peptide preparation Epithalamin on free-radical processes in humans and rats. Neuro Endocrinol Lett. 2001;22(1):9-18. PMID: 11335874
3. Khavinson VK, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003;24(3-4):233-240. PMID: 14523363